Premium
Use of aspirin in older individuals not found to reduce cognitive decline
Publication year - 2020
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30595
Subject(s) - aspirin , dementia , cognitive decline , medicine , placebo , cognition , cognitive impairment , gerontology , low dose aspirin , population , disease , psychiatry , environmental health , alternative medicine , pathology
Daily low‐dose aspirin showed a consistent lack of benefit on rates of Alzheimer's disease, mild cognitive impairment, and cognitive decline in a placebo‐controlled trial involving healthy older adults. The results follow earlier findings of no benefit of aspirin in prolonging disability‐free survival or decreasing the risk of incident dementia in the same study population.